Study Summary
RATIONALE: Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is resistant or refractory to chemotherapy.
Want to learn more about this trial?
Request More InfoInterventions
anti-CD20-CAR vector-transduced autologous T cellsBIOLOGICAL
anti-CD20-CAR vector-transduced autologous T cells
genetically engineered lymphocyte therapyOTHER
genetically engineered lymphocyte therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Biotherapeutic Department of Chinese PLA General Hospital | Beijing | Beijing Municipality | China |